Background-Although the benefits of cardiac resynchronization therapy are well established in selected patients with heart failure and a prolonged QRS duration, salutary effects in patients with narrow QRS complexes remain to be demonstrated. Methods and Results-The Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial is a randomized, double-blind, 12-center study that was designed to compare the effects of active and inactive cardiac resynchronization therapy in patients with severe left ventricular dysfunction and a QRS duration <120 milliseconds. 
H eart failure (HF) is considered an epidemic of the modern era. [1] [2] [3] Cardiac resynchronization therapy (CRT) has emerged as a valuable adjunctive therapy for patients with severe HF and a prolonged QRS duration. In selected candidates on optimal medical therapy, studies have shown that CRT reduces cardiac-related hospitalizations and improves New York Heart Association (NYHA) functional class, exercise tolerance, left ventricular (LV) systolic function, and survival. [4] [5] [6] [7] [8] Response to CRT in patients with severe HF and a QRS duration <120 milliseconds is less well established. Although small single-center studies support the hypothesis that such patients may also benefit from CRT, most reports are observational in nature. [9] [10] [11] [12] [13] To date, 1 clinical trial found no benefit of CRT in 178 patients with a QRS duration <130 milliseconds. 14 Moreover, a single-arm feasibility study of CRT in 68 patients with a QRS duration <120 milliseconds was recently abandoned because of lack of benefit. 15 The primary outcome for both studies was maximum oxygen uptake (peak . Vo 2 ), which has been criticized for its poor sensitivity in detecting therapeutic responses. In contrast, a nonblinded, randomized trial that compared CRT
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and optimal medical therapy (with no device implantation) in patients with a QRS duration <120 milliseconds reported improvements in symptoms, exercise capacity, and quality of life with CRT. 16 
Clinical Perspective on p 881
We conducted a randomized, double-blind, multicenter clinical trial, the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH), to assess whether CRT therapy improves exercise capacity as measured by a standardized submaximal exercise treadmill test (primary outcome) and LV reverse remodeling outcomes in patients with an LV ejection fraction (LVEF) ≤35%, symptoms of HF, and a QRS duration <120 milliseconds.
Methods
Study Population
Patients were recruited from 12 sites across Canada (see the onlineonly Data Supplement). Each participating institution obtained approval from its local institutional review board. Eligibility criteria consisted of a clinical indication for an implantable cardioverterdefibrillator (ICD), a qualifying LVEF ≤35% measured within the previous 6 months (without a major intercurrent event such as cardiac surgery), a QRS duration <120 milliseconds, and symptoms of HF with a 6-minute walk test distance ≤400 m limited by symptoms of HF. 17 In a manner consistent with clinical guidelines for CRT, hospitalization for HF was not required. There was no prerequisite for LV dyssynchrony and no inferior limit for QRS duration. Patients in permanent atrial fibrillation, those limited by factors other than HF symptoms (eg, angina, intermittent claudication, significant heart valve stenosis, or osteoarthritis), and those with a recent myocardial infarction or cardiac surgery (<6 weeks) were excluded. Patients with prior pacemakers or ICDs considered for an upgrade to CRT were eligible, provided that their percentage of ventricular pacing was ≤5%. Patients with previously implanted CRT systems were excluded.
Study Design
A randomized, double-blind study was conducted. After providing written informed consent, all patients received a CRT-ICD system from St. Jude Medical (Minnetonka, MN). There was a 2-to 8-week "run-in period" during which CRT was programmed "off" and the atrioventricular (AV) delay was set to ≥325 milliseconds. This period allowed the maturation of the CRT-ICD system and optimization of pharmacological therapy if needed. At the end of this run-in phase, patients were required to conform to inclusion and exclusion criteria to remain eligible for randomization. Stable doses of β-blockers and angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers at maximally tolerated levels were mandated for a minimum of 4 weeks before the baseline assessment was conducted. Those no longer meeting eligibility criteria were excluded from the study and offered the opportunity to be followed up in a nonrandomized registry.
In qualifying patients, a comprehensive baseline assessment was performed consisting of a medical questionnaire; physical examination; cardiopulmonary exercise test with a ramp protocol with gas exchange analyses, submaximal exercise with a constant-load protocol, and 6-minute walk test; and quality-of-life questionnaires (ie, Short Form-36 and the Minnesota Living With Heart Failure questionnaire). 18 LV function, geometry, and metrics of synchrony were assessed by echocardiography and by nuclear ventriculography. This complete evaluation was repeated after 6 and 12 months.
Clinical and quality-of-life questionnaires were administered by independent staff blinded to device programming. Exercise testing, quality-of-life assessment, and imaging studies were performed locally, with source material transferred to independent core laboratories (Montreal Heart Institute) for blinded assessment. The study was initiated in 2003, registered at http://www.clinicaltrials.gov under the identifier NCT00900549, and funded by the Canadian Institutes for Health Research (grant 67914) in partnership with St. Jude Canada. All adverse events were classified by a blinded adjudicating committee. An independent Data and Safety Monitoring Board was tasked with evaluating patient safety data. At its last biannual meeting, the steering committee also requested that the Data and Safety Monitoring Board review efficacy data and provide recommendations on continuation, modification, or termination of the trial. On the strong recommendation of the Data and Safety Monitoring Board, the study was terminated prematurely in January 2011 for futility and potential concerns about patient safety.
The authors were solely responsible for the design and conduct of the study, vouch for the data and analysis, and wrote the manuscript without assistance. The study was conducted in compliance with the Canadian Privacy Legislation and the World Medical Association Declaration of Helsinki (2002).
CRT-ICD Programming
At randomization, devices were programmed in the DDD mode at a base rate of 40 bpm. Faster rates were considered protocol deviations and required a waiver. Use of the activity sensor was strictly forbidden throughout the study for risk of interference with exercise testing. Optimal AV delays (AS-VP and AP-VP) were established at baseline with an ECG method: Repeated 12-lead ECGs were performed with AV delays ranging from 80 to 250 milliseconds at each 10-millisecond increment. The longest AV delay that fully captured the ventricles (ie, no fusion with intrinsic conduction) during simultaneous biventricular pacing was identified (average, 99±13 milliseconds; range, 90-150 milliseconds). This AV delay was programmed for each patient randomized to CRT-on and kept constant for the duration of the study. In the CRT-off group, AV delays of 325 to 350 milliseconds (AS-VP and AP-VP) were used.
Study Outcomes
Primary Outcome
The primary outcome consisted of submaximal exercise duration (expressed in minutes). Each patient's maximal cardiopulmonary exercise capacity was assessed with a previously described continuous, progressive exercise treadmill test with an individualized ramp protocol. 19 The submaximal treadmill test was performed using a constant-load protocol at an intensity corresponding to 75% of the peak . Vo 2 determined by the maximal exercise test. 20, 21 After a 2-minute warm-up (1 mph, no slope), the slope and speed of the treadmill were programmed to predetermined settings corresponding to 75% of peak . Vo 2 . Heart rate was measured for 5 minutes into recovery. The test was terminated on exhaustion or after 25 minutes of exercise (itself an exclusion criterion from randomization) at baseline or after 45 minutes at 6 and 12 months.
Secondary Outcomes
Secondary outcomes included LVEF, LV end-systolic volume, interventricular and intraventricular delays, NYHA functional class, quality-of-life metrics, distance covered during the 6-minute walk test, and NT-pro-brain natriuretic peptide levels. A positive clinical response was defined as a ≥20% increase in exercise duration. A positive remodeling response was defined as a ≥15% reduction in LV end-systolic volume.
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Statistical Analyses
Data management and analyses were performed by the Montreal Heart Institute Coordinating Center. A sample size of 104 patients was required to provide 80% power to detect a 5-minute difference by guest on July 26, 2017 http://circ.ahajournals.org/ Downloaded from in mean exercise duration between the 2 pacing modalities (deemed clinically relevant), assuming a 2-tailed value of α=0.05. To allow for a 15% loss to follow-up, 120 patients were targeted for randomization.
Continuous variables are summarized as mean±SD unless otherwise specified. Categorical variables are represented by frequencies and percentages. For continuous efficacy end points, changes from baseline to 6 and 12 months were assessed with ANCOVA models that included terms for pacing mode (CRT on versus off) and baseline values of response variables as covariates. Adjusted mean values for each pacing mode were provided, along with 95% confidence intervals. We used χ 2 tests for categorical efficacy end points such as NYHA functional class and response to CRT at 6 and 12 months. Prespecified subgroup analyses were performed for 3 baseline characteristics: sex, type of LV dysfunction (ie, ischemic versus nonischemic), and QRS duration <100 versus ≥100 milliseconds. Each subgroup analysis was performed with the ANCOVA models described above with additional terms for subgroup and its interaction with pacing mode. The interaction term was tested at the 0.05 level to assess whether the impact of pacing mode was similar across subgroups. To assess the reliability of echocardiographic measurements, a random sample of 20 recordings were evaluated twice by 2 core laboratory sonographers. Intraobserver reliability and interobserver reliability were assessed with intraclass correlation coefficients. All analyses were performed under the intentionto-treat principle. All tests were 2 sided and conducted at the 0.05 significance level. Statistical analyses were performed with SAS version 9.2.
Results
Study Population
The study was prematurely terminated for futility and potential harm after enrolling 159 patients ( Figure 1 ). To qualify for randomization at the end of the run-in period, patients were required to have a functional CRT system, to continue to meet inclusion criteria, and to remain capable of performing exercise tests. Reasons for which enrolled patients were excluded from randomization (n=74) were the following: major problems with the CRT system (n=34), including failure to implant the LV lead (n=25), lead dislodgment, or malfunction (n=9); inability to perform exercise testing (n=5) or exercise threshold surpassed (n=11); prohibitive comorbid conditions (n=3); withdrawal of consent (n=8); LVEF ≥40% at baseline (n=2); percentage of ventricular pacing >5% in CRT-off group and/or atrial fibrillation >10% (n=3); resynchronization therapy activated before baseline evaluation (n=4); and premature study termination before baseline evaluation (n=4). Of the 85 randomized patients, 7 patients subsequently dropped out as a result of noncompliance (n=5) or the treating physician's decision not to reintervene on a dislodged lead (n=2).
Patient Characteristics
Baseline characteristics according to whether patients were randomized to active or inactive CRT therapy are summarized in Table 1 . The mean qualifying LVEF was 25.2±6.2% in patients randomized to CRT-on and 24.7±4.5% in patients with CRT-off. Respective mean baseline QRS durations were 105.0±9.9 and 105.3±10.3 milliseconds. At inclusion, 93.2% and 100% of patients were on β-blockers, and 95.5% and 100% received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, respectively. These proportions remained stable (≥95%) during the course of the study.
Exercise Duration
As shown in Table 2 , the primary outcome, change from baseline in exercise duration at the predefined submaximal level, was similar in patients randomized to CRT-on and those randomized to CRT-off at 6 months (P=0.62) and 12 months (P=0.31). In patients randomized to CRT-on, the nominal change in exercise duration from baseline was 0.3 minutes (95% confidence interval [CI], −1.4 to 2.0) and −0.7 minutes (95% CI, −2.9 to 1.5) at 6 and 12 months, respectively. Nominal changes in exercise duration for patients randomized to CRT-OFF were 0.9 minutes (95% CI, −0.9 to 2.7) and 0.8 minutes (95% CI, −1.2 to 2.9) at 6 and 12 months. Corresponding between-group differences were −0.6 (95% CI, −3.1 to 1.9) at 6 months and −1.5 (95% CI, −4.6 to 1.5) at 12 months, respectively. No statistically significant interaction was noted between pacing mode and predefined subgroups (sex, ischemic versus nonischemic cardiomyopathy, and QRS duration <100 versus ≥100 milliseconds).
QRS Duration and 6-Minute Walk Distance
Effects of CRT therapy on other secondary end points are also summarized in Table 2 . A much greater increase in QRS duration from baseline to 6 and 12 months was observed in patients with active CRT therapy (41. , respectively. The 6-minute walk distance increased significantly from inclusion to baseline assessment in patients with (282.6±70.9 to 342.2±86.2 m) and without (318.6±80.0 to 362.3±77.9 m) active CRT therapy. Thereafter, in patients with active CRT therapy, the 6-minute walk distance decreased by an average of 5.4. m (95% CI, −20.5 to 9.6) and 11.3 m (95% CI, −31.7 to 9.7) at 6 and 12 months. In contrast, the 6-minute walk distance increased by an average of 14.8 m (95% CI, 0.1-29.5) and 25.3 m (95% CI, 6.1-44.5) in patients with inactive CRT at 6 and 12 months (P=0.06 and P=0.01, respectively).
Functional Status and Quality of Life
At the time of inclusion, 54.5% and 51.2% of patients had NYHA functional class III-IV symptoms with and without active CRT therapy, respectively. The greatest reduction in the proportion of patients with class III-IV symptoms occurred during the run-in phase before randomization, that is, to 39.5% and 29.3%. During the run-in period, the metoprolol-equivalent dose of β-blockers decreased in 4% of patients, increased in 16% of patients, and remained the same in 80% of patients. There were no significant changes in dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Importantly, there was no significant difference between the change in NYHA functional class (P=0.44) or the change in 6-minute walk distance (P=0.96) between patients with no change or a decrease in dose of β-blockers and those with an increased dose of β-blockers. After randomization, no significant differences in NYHA functional class and health-related quality-of-life scores were observed in patients with and without active CRT therapy.
LV Size and Function
As shown in Table 3 , there were no significant differences in LV end-systolic volume and LVEF as assessed by echocardiography and nuclear ventriculography in patients with active and inactive CRT. Interventricular dyssynchrony (ie, right ventricular-LV delay) was likewise similar between the 2 groups by both methods of assessment. However, discrepancies were observed for intraventricular activation. Whereas echocardiography revealed no difference in the delay between contraction of the lateral and septal walls, with nuclear ventriculography, Figure 2 ). Good intraobserver (intraclass correlation coefficient, 0.95-1.00) and interobserver (intraclass correlation coefficient, 0.78-0.96) correlations were noted for echocardiographic parameters, the lowest values being for intra-LV dyssynchrony. Correlations were all >0.97 for values derived by nuclear medicine.
Response to Therapy
A clinical response, defined by a ≥20% improvement in duration of submaximal exercise, was noted in 10 of 31 patients (32.3%) with active CRT and 13 of 35 patients (37.1%) with CRT-off (P=0.68). Similarly, a favorable reverse LV remodeling response, defined by a ≥15% relative reduction of LV endsystolic volume, was observed in 10 of 30 patients (33.3%) with active CRT compared with 8 of 30 patients (26.7%) with CRT-off (P=0.57) by echocardiography and in 6 of 32 patients In a manner similar to single-photon emission computed tomography scans, the left ventricular apex is depicted at the center; the base, at the periphery; the septum (Sept), on the left; lateral (Lat) free wall, on the right; anterior wall (Ant), on top; and inferior (Inf) wall, at the bottom. A cardiac cycle covers 360° (from −180° to 180°). The baseline polar map shows a predominantly homogeneous pattern of activation (light blue), with the exception of delayed contraction at the apex (red), consistent with a prior apical infarction. Right, Increased inhomogeneity of ventricular contraction as reflected by the less uniform color-coded pattern. A leftward phase shift is observed, with delayed contraction of the septal wall (red) relative to the anterolateral wall (blue). In this particular patient, CRT-induced left ventricular dyssynchrony was associated with a reduction in left ventricular ejection fraction (from 33% to 22%) and increased end-systolic volume (from 241 to 280 mL). 
LV Lead Position
The LV lead was in a lateral position in 40 of 44 patients (90.9%) randomized to CRT and 41 of 41 control subjects (100%; P=0.12). It was apically positioned in 9 of 44 patients (20.5%) randomized to CRT and 8 of 41 control subjects (19.5%; P=0.91). Position of the LV lead had no impact on exercise tolerance or LV reverse remodeling outcomes.
Adverse Events
Two patients died during the course of the study, both of whom were randomized to active CRT; 1 patient died of HF and 1 died of cancer. Five patients with active CRT were hospitalized 15 times for HF (1 patient had 8 hospitalizations) compared with 4 patients hospitalized once each with inactive CRT. As shown in Figure 3 , time to first hospitalization for HF was not significantly different between the 2 groups (logrank P=0.69). In addition, 5 patients had arrhythmic events (4 atrial, 1 ventricular) with active CRT compared with 8 patients (6 atrial; 4 ventricular events [nonexclusive categories]) with inactive therapy. The difference was not significant (P=0.30).
Discussion
In this randomized, clinical trial, we tested the hypothesis that CRT would improve exercise tolerance and reverse LV remodeling in patients with severe HF (LVEF ≤35%) and a QRS duration <120 milliseconds. The qualifying 6-minute walk test distance at inclusion was comparable to that in patient populations enrolled in the contemporary Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT) 23 and Resynchronization/ Defibrillation for Ambulatory Heart Failure Trial (RAFT) 24 trials. The LESSER-EARTH trial was terminated prematurely after enrolling and randomizing 159 and 85 patients, respectively, because of futility and safety concerns. Although no differences were observed with regard to the primary outcome and LV size and function, CRT was associated with a significant prolongation of QRS duration, a significant reduction in the 6-minute walk distance, and a nonsignificant trend toward increased HF-related hospitalizations. To the best of our knowledge, these results provide the most compelling evidence to suggest that CRT can worsen or provoke dyssynchrony in patients with little or no dyssynchrony to begin with.
Importantly, LESSER-EARTH, like the Resynchronization Therapy in Normal QRS (RETHINQ) 14 and Evaluation of Screening Techniques in Electrically-Normal, MechanicallyDyssynchronous Heart Failure Patients (ESTEEM-CRT) 15 trials, relied on functional metrics and indexes of reverse remodeling as opposed to hard clinical outcomes such as mortality. Nevertheless, these studies have consistently failed to demonstrate a benefit from CRT in patients with a narrow QRS complex. The primary outcome for RETHINQ 14 and ESTEEM-CRT 15 was maximum oxygen uptake (peak . Vo 2 ) as assessed by cardiopulmonary exercise testing, which has been criticized for its lack of sensitivity in detecting therapeutic responses, potential to be poorly tolerated by patients with HF, and need for careful calibration. 25 In contrast, the submaximal exercise treadmill test, as performed in LESSER-EARTH, is an alternative and highly reproducible method that is simple to administer, has greater sensitivity in detecting therapeutic responses, and is generally well tolerated by patients with HF. 26 Despite this more sensitive assessment, results on the lack of benefit from CRT remained consistent.
Interestingly, Foley et al 16 reported divergent results favoring CRT compared with optimal medical therapy in 60 patients with an LVEF<35% and a QRS duration <120 milliseconds. Improvements in symptoms, exercise capacity, and quality of life were observed. 16 The discrepancy with other clinical trials may reflect important methodological differences, including Time to first hospitalization for heart failure in patients randomized to active vs inactive cardiac resynchronization therapy (CRT). Kaplan-Meier product-limit curves show survival free from hospitalization for heart failure in patients randomized to active vs inactive CRT. February 26, 2013 the absence of device implantation in control subjects. The EARTH studies 26 have highlighted the importance of blinding and of including a time period between implantation of a device and baseline assessment for titration of medical therapy. The greatest improvement in softer end points such as NYHA functional class and 6-minute walk tests occurred during this prerandomization phase, that is, after device implantation and before activation of CRT. Underlying reasons for these early improvements may include a placebo effect and/or further optimization of pharmacological therapy after device implantation. Such a run-in period allows patients who no longer qualify to be excluded from randomization and mitigates potential overestimation of early benefits of CRT. Indeed, in a manner similar to LESSER-EARTH, Foley et al 16 found no benefit of CRT with regard to metrics of LV remodeling.
Another important methodological difference between LESSER-EARTH and other studies was that ventricular dyssynchrony, determined by an imaging study, was not required for inclusion. This was deemed appropriate in light of the absence of a widely accepted imaging marker for dyssynchrony with demonstrated value in predicting response to CRT. In the LESSER-EARTH trial, dyssynchrony was systematically assessed by both echocardiography and nuclear ventriculography in all patients for exploratory analyses. Baseline interventricular and intraventricular delays were not predictive of clinical response or reverse LV remodeling. Interestingly, nuclear ventriculography detected a leftward shift (ie, toward the negative phase) during CRT, reflecting preexcitation of the lateral wall. Although further studies are required to determine whether such indexes bear any clinical relevance, the lack of a reverse remodeling response to CRT is fully consistent with the lack of benefit observed across all primary and secondary outcome metrics. Moreover, echocardiographic findings are consistent with the RETHINQ 14 and ESTEEM-CRT 15 trials. Importantly, the ongoing Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) trial (www. ClinicalTrials.gov; identifier, NCT00683696) was specifically designed to assess the impact of CRT on morbidity and mortality in >1250 patients with a narrow QRS complex and ventricular dyssynchrony by echocardiography. Our results may also be contrasted with the GREATER-EARTH study in which contemporary patients were subjected to the same protocol, definitions, means of assessing outcomes, core laboratories, and inclusion/exclusion criteria except for QRS duration. 26, 27 Whereas CRT resulted in a 50% improvement (5 minutes) in exercise duration in patients with a QRS complex ≥120 milliseconds, no such benefit occurred if the QRS duration was <120 milliseconds. Similarly, CRT resulted in highly significant reverse LV remodeling effects in patients with a wide QRS complex (6% in LVEF, 30-mL reduction in LV end-systolic volume) but no change in patients with a narrow QRS complex. Taken together, these results challenge prior nonrandomized studies that reported similar benefits from CRT regardless of QRS duration but lacked a control group with inactive CRT therapy.
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Study Limitations
A higher-than-projected proportion of patients (40%) initially enrolled in the prerandomization phase did not proceed to randomization, underscoring the difficulties associated with implantation and proper functioning of the device (ie, 40% of patients were not randomized for this reason). The higher-thananticipated implant failure rate (ie, 15%) is unlikely to reflect a lack of operator experience because the same investigators reported a 4% implant failure rate in a trial conducted simultaneously. 24 Underlying reasons remain speculative but may include a lower threshold to abandon difficult procedures in the absence of convincing clinical indications. Rather than randomizing all patients with implanted CRT systems, subjects were required to conform to inclusion and exclusion criteria after a 2-to 8-week run-in period (during which CRT was off). This step was critical for maximizing the quality of the randomized study and ensures that the observed lack of benefit/ potential harm was not confounded by suboptimal CRT delivery. However, this requirement contributed to a substantially longer recruitment period, which may affect the generalizability of the study results. Nevertheless, the exclusion of inappropriate candidates represents a desirable trade-off in maximizing internal validity. Moreover, study power for outcomes such as hospitalizations was limited by early study termination.
Conclusions
The LESSER-EARTH trial, which randomized patients with an LVEF ≤35%, symptoms of HF, and a QRS duration <120 milliseconds to active versus inactive CRT therapy, was terminated prematurely because of futility and safety concerns. CRT did not result in an improvement in exercise capacity, symptoms, quality of life, or reverse LV remodeling. Moreover, CRT was associated with a significant reduction in the 6-minute walk distance, an increase in QRS duration, and a nonsignificant trend toward an increase in HF-related hospitalizations.
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